Keryx Biopharmaceuticals (KERX) PT Cut to $22 at Brean Capital Following Q2; Upside Seen Over 200%
Tweet Send to a Friend
Brean Capital analyst Jonathan Aschoff lowered his price target on Keryx Biopharmaceuticals (NASDAQ: KERX) to $22.00 (from $26.00) following Q2 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
